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Abstract
Rates of depression are high among individuals living with HIV. Accurate assessment of 
depressive symptoms among this population is important for ensuring proper diagnosis and 
treatment. The Beck Depression Inventory-II (BDI-II) is a widely used measure for assessing 
depression, however its psychometric properties have not yet been investigated for use with HIV-
positive populations in the U.S. The current study was the first to assess the psychometric 
properties of the BDI-II among a large cohort of HIV-positive participants sampled at multiple 
sites across the U.S. as part of the CNS HIV Antiretroviral Therapy Effects Research 
(CHARTER) study. The BDI-II test scores showed good internal consistency (α = 0.93) and 
adequate test-retest reliability (ICC = 0.83) over a 6-month period. Using a ‘gold standard’ of 
major depressive disorder determined by the Composite International Diagnostic Interview 
(CIDI), sensitivity and specificity were maximized at a total cut-off score of 17 and a Receiver 
Operating Characteristic (ROC) analysis confirmed that the BDI-II is an adequate diagnostic 
measure for the sample (AUC = 0.83). The sensitivity and specificity of each score are provided 
graphically. Confirmatory factor analyses confirmed the best fit for a 3-factor model over 1-factor 
and 2-factor models and models with a higher-order factor included. The results suggest that the 
BDI-II is an adequate measure for assessing depressive symptoms among U.S. HIV-positive 
patients. Cut-off scores should be adjusted to enhance sensitivity or specificity as needed and the 
measure can be differentiated into cognitive, affective, and somatic depressive symptoms.
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The rates of depression in HIV-positive populations are double that of the general 
population (Ciesla & Roberts, 2001; Penzak, Reddy, & Grimsley, 2000). The consequences 
of depression in HIV are profound and include worse medication adherence (Ammassari et 
al., 2004; Patterson, Swindells, & Mohr, 1999; Singh & Squier, 1996), alterations in the 
immune system (Leserman, 2003; Lyketsos, Hoover, & Guccione, 1993; Patterson et al., 
1999), higher rates of risky sexual and drug use behaviors (Hutton, Lyketsos, Thompson, & 
Erbelding, 2004; Perdue, Hagan, Thiede, & Valleroy, 2003), and premature death (Pyne et 
al., 2008). The BDI-II, one of the most widely used self-report measures for assessing 
depression among the general population, frequently serves as an index of depressive 
symptoms in research with HIV-infected samples (Berger-Greenstein et al., 2007; Kagee, 
Nel, & Saal, 2013; Rosenbloom et al., 2007).
Despite its wide use, only two studies to date examined the psychometric properties of the 
BDI-II among individuals with HIV/AIDS. Lipps and colleagues (Lipps et al., 2010) 
administered the BDI-II to 191 HIV-positive individuals recruited through HIV clinics in 
Kingston and St. Andrew, Jamaica. The BDI-II test scores showed good internal consistency 
with a cronbach’s coefficient alpha of 0.89, and the score interpretations had good 
convergent validity (r = 0.74) with the Center for Epidemiological Studies -Depression 
Scale (Lipps et al., 2010) and discriminant validity (r = −0.42) with the Social Provisions 
Scale (Cutrona & Russell, 1987). A three-factor solution of cognitive, affective, and somatic 
symptoms emerged using a principal components analysis with oblique rotation. More 
recently, Kagee, Nel, and Saal (2013) administered the BDI-II to a group of 185 HIV-
positive South Africans and found good internal consistency (α = .90) and a three-factor 
solution of cognitive, affective, and somatic symptoms using principal components analysis 
with orthogonal rotation. Previous research suggests that the experience of living with HIV 
and depressive symptoms are influenced by cultural factors such as stigma, cultural beliefs, 
and collective knowledge (Airhihenbuwa, Ford, & Iwelunmor, 2013; Cain et al., 2013; 
Walsh & Cross, 2013). These cultural factors may influence the validity of the BDI-II 
among varying populations and geographic regions, thus warranting a thorough examination 
of the BDI-II among a U.S. population as well.
Studies exploring the factor structure of the BDI-II among HIV seronegative samples have 
consistently found 2- and 3-factors solutions using both exploratory and confirmatory factor 
analyses (CFA) (Al-Musawi, 2001; Dozois, Dobson, & Ahnberg, 1998; Vanheule, Desmet, 
Groenvynck, Rosseel, & Fontaine, 2008). There is also support for an underlying, higher-
order factor often labeled general depression or general distress (Steer, Clark, Beck, & 
Ranieri, 1998). No study to date has examined the factor structure of the BDI-II among an 
adequately sized sample of HIV-positive patients within the U.S..
The diagnostic value of the cut-off scores outlined by Beck and colleagues (Beck, Steer, & 
Brown, 1996) has not been validated within an HIV-positive population. Commonly used 
diagnostic values include sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV). Sensitivity is the proportion of participants diagnosed with 
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MDD that are correctly identified by the BDI-II cut-off score. Specificity is the proportion 
of participants not diagnosed with MDD that are correctly identified by the BDI-II cut-off 
score. Positive predictive value is the probability that a participant has MDD given that they 
are above the designated BDI-II cut off score. Negative predictive value is the probability 
that a participant does not have MDD given that they are below the designated BDI-II cut 
off score.
In the original validation, Beck and colleagues (Beck et al., 1996) conducted Receiver 
Operating Characteristics (ROC) analyses with data collected from psychiatric outpatients. 
The calculated Area Under the Curve (AUC) value, which is an index of the amount of 
diagnostic information provided by the measure, ranges from 0.0 (no information) to 1.0 
(perfect diagnostic accuracy) and values .80 and above represent a useful screening 
instrument (Arnau, Meagher, Norris, & Bramson, 2001; Holmes, 1998). Beck and 
colleagues conducted 3 ROC analyses comparing categories of depression severity. They 
used the cut-off score in each analysis that best maximized sensitivity and specificity to 
develop the commonly used classifications, however they did not report specific diagnostic 
values for each.
Sensitivity and specificity varies for BDI-II cut-off scores depending on the population 
sampled. An ROC analysis with BDI-II scores collected from a sample of primary care 
patients showed an AUC of .96, indicating excellent predictive validity. A cut-off score of 
18 provided the best balance between sensitivity (94%) and specificity (92%). An AUC of .
91 was determined with BDI-II scores collected from African American primary care 
patients and a cut-off score of 14 provided the best balance between sensitivity (88%) and 
specificity (84%) (Dutton et al., 2004). The appropriate cut-off score for use with HIV-
positive individuals has not yet been determined.
The current study examined the psychometric properties of the BDI-II among a large, 
sample of HIV-positive patients recruited in the United States. The findings provide 
information on the reliability, factor structure, and diagnostic characteristics of the BDI-II 
for use with HIV-positive populations.
Methods
A cross-sectional examination was conducted using data collected from the CHARTER 
study to assess the psychometric properties of the BDI-II among a large, U.S. based sample 
of individuals with HIV/AIDS. The CHARTER study is a multi-site, prospective, 
observational study funded by the National Institute of Mental Health and the National 
Institute of Neurological Disorders and Stroke and was conducted at the following six North 
American medical centers from 2003 to 2007: Johns Hopkins University, Baltimore, MD; 
The Mount Sinai School of Medicine, New York, NY; University of California, San Diego, 
San Diego, CA; University of Texas, Medical Branch, Galveston, TX; University of 
Washington, Seattle, WA; and Washington University, St. Louis, MO. Local Institutional 
review boards approved research at each site and all participants provided written informed 
consent. Participants were eligible to participate in the CHARTER study if they were HIV-
positive, able to provide written informed consent, and able to complete baseline 
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assessments. The minimal exclusion criteria included only the inability to complete 
assessments. Of the 1,900 patients asked to participate, 78.1% agreed. The 317 patients that 
refused had lower education levels, higher rates of female gender, and nonwhite ethnicity 
compared to the study participants. The total sample collected at time 1 consisted of 1,583 
HIV-positive individuals from diverse backgrounds recruited to be reflective of patients at 
university-affiliated HIV treatment centers. A smaller group of participants (n=698) returned 
for follow-up data collection 6 months later. These participants were selected on the basis of 
identified groups of interest with characteristics whose long-term follow-up would shed 
additional light on important questions in regards to neurological function in the context of 
HAART. Participants completed thorough neuromedical and neurobehavioral assessments at 
each time point. Only the measures of mood and depression were used for the current 
investigation.
Measures
The BDI-II (Beck et al., 1996) is a measure of self-reported depression and mood. The items 
include an assessment of 21 behavioral and observable symptom areas covering a range of 
emotional, cognitive, motivational, and somatic components of clinical depression designed 
to reflect the depressive episode criteria outlined in the DSM-IV (American Psychiatric 
Association, 1994; Beck & Beamesderfer, 1974). It can be conducted with persons 13 to 80 
years of age, requires approximately 5 to 10 minutes to complete, and can be read to 
respondents who may have difficulty reading independently. The BDI-II is scored by 
summing the ratings, which are each scored on a 4-point scale ranging from 0 to 3, with a 
range from 0 to 63. This measure was designed as a tool for determining depressive 
symptom type and severity and not as a diagnostic tool (Beck et al., 1996). However, the 
BDI-II is often used as a diagnostic or screening tool with the cutoff-scores determined 
during the original validation with psychiatric outpatients: 0-13 minimal, 14-19 mild, 20-28 
moderate, 29-63 severe. The complete manual and scoring kit, including 25 record forms, 
can be purchased from Pearson (San Antonia, TX) for $125.00. Pearson also offers a web-
based scoring and reporting platform, Q-global™, that produces interpretive reports for 
$3.00 each.
The Composite International Diagnostic Interview (Robins et al., 1988) is a structured 
interview designed to assess the quality and severity of substance use disorders and mental 
disorders as outlined in the International Classification of Diseases (9th revision) and the 
Diagnostic and Statistical Manual of Mental Disorders III. Reliability and validity have been 
shown across cultures around the world (Robins et al., 1988). For the current study, all 
assessors were trained and certified by the Psychiatric Coordinator at the Coordinating 
Center, and provided tape recordings of their first 15 CIDI interviews, which to the protocol 
and reliability. All assessors were re-certified on CIDI administration on an annual basis.
Statistical Analyses
All statistical analyses were conducted using SPSS 20 (IBM Corp, Released 2011) or Mplus 
Version 6 (Muthén & Muthén, 1998-2012). Chi-square tests of independence and 
independent t-tests were conducted to identify significant differences between the time 1 and 
2 samples. Internal consistency was examined using cronbach’s coefficient alpha. Intraclass 
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correlation coefficients were used to assess test-retest reliability for the BDI-II total score 
and individual items. Logistic regression assessed the predictive validity of the BDI-II test 
score interpretations. Current major depressive disorder (MDD) at time 2 was regressed onto 
BDI-II total score at time 1, while controlling for current MDD at time 1.
Sensitivity, specificity, PPV, and NPV were calculated to examine the BDI-II as a tool for 
screening and diagnosing MDD among HIV-infected individuals. ROC curves and AUC 
values were calculated and the ‘gold standard’ of MDD for the current sample was 
determined by the CIDI. The ROC analyses were conducted with time 1 data only.
CFA tested one-, two-, and three-factor solutions to account for variation in individual BDI-
II items. The two- and three-factors solutions were also conducted with a higher-order factor 
included in the model to assess for improvement in fit. The CFAs were run with time 1 and 
2 data to assess for reliability across samples. For the CFAs, weighted least squares with 
parameter estimates (WLSMV) were used to calculate chi-square test statistics (χ2) root 
mean square error of approximation (RMSEA), comparative fit index (CFI), Tucker-Lewis 
fit index (TFI), and goodness of fit index (GFI).
Chi-square difference tests, a common method of comparing nested models, cannot be used 
to compare the present models for two reasons; 1) WLSMV produces a between-model 
value that is not distributed as chi-square (Byrne, 2012, p.139) and, 2) Mplus does not deem 
the current models as nested., which Brown (2006, p.164) explains concisely. Thus, the 
CFAs were rerun using maximum likelihood parameter estimates (MLR) that are robust to 
non-normality and non-independence of observations to allow for comparison across models 
using Akaike Information Criterion values (AIC). AIC was used to compare the overall fit of 
competing, non-nested models, with lower values indicating a better fit (Brown, 2006, p.
180).
The factors tested in the current analyses were pre-specified based on the two-factor model 
derived by Beck and colleagues (Beck et al., 1996) with a sample of 277 psychiatric 
outpatients using promax-rotated iterated-principal factor analysis, and the three-factor 
model derived by Buckley and colleagues (Buckley, Parker, & Heggie, 2001) using CFAs 
with a sample of 416 men admitted to a residential substance use program at a Veteran’s 
Affairs Medical Center. The models are displayed in Figures 1 and 2, respectively. These 
two models were chosen for the current study based on evidence from a large comparison 
study conducted by Vanheule and colleagues (Vanheule et al., 2008), who found these two 
models to have the best fit when compared to five alternative two-factor models and four 
alternative three-factor models across clinical and non-clinical adult samples.
All secondary data analyses were approved by the University at Albany, State University of 
New York Institutional Review Board.
Results
The demographic, disease, and medical comorbidity characteristics of the time 1 and 2 
samples are displayed in Table 1. The time 2 sample was significantly older, had higher 
CD4 absolute cell counts, lower viral load counts, less medical comorbidities, and less HIV-
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associated neurocognitive impairment. Current and lifetime psychiatric and substance use 
diagnoses are displayed in Table 2. The time 1 sample had significantly more diagnoses of 
current MDD. Statistics for the BDI-II items and total scores for time 1 and time 2 data are 
displayed in Table 3. The time 1 sample had significantly higher BDI-II scores (t(2261)= 
3.85, p<.01). The mean BDI-II total score found among the time 1 sample was similar to 
other samples of individuals living with HIV (Lipps et al., 2010; Rosenbloom et al., 2007) 
and lower than HIV-positive participants with significant substance use and psychiatric 
morbidities (Berger-Greenstein et al., 2007). Internal consistency was good for time 1 (α = 
0.93) and time 2 (α = 0.94). Test-retest reliability was adequate for the total score (ICC = 
0.83) considering depressive symptoms were expected to change over the 6-month period 
between BDI-II administrations. Intraclass correlation coefficients varied for each BDI-II 
item with the lowest reliability coefficient for changes in appetite (ICC = 0.48) and the 
highest for loss of interest in sex (ICC = 0.75).
Logistic regression analyses indicated that BDI-II total score at time 1 successfully 
distinguished between those with and without a diagnosis of MDD at time 2, χ2 (2, 697) = 
81.30, p < .001. The odds of being diagnosed with MDD at time 2 were 1.1 greater with 
every one-unit increase in BDI-II score at time 1. Classification however, was unimpressive, 
with 11% of those with MDD and 99% of those without MDD correctly predicted, for an 
overall success rate of 89%.
The sensitivity, specificity, PPV, and NPV at each BDI-II value are displayed in Figures 3 
and 4, respectively. The BDI-II had equal sensitivity and specificity (74%) at a cut-off of 17, 
meaning that 74% of those with depression and without depression were correctly identified 
using a cut-off of 17. Sensitivity increased to 90% at a cut-off of 10; however, specificity 
decreased to 52%, suggesting that approximately half of those without depression will be 
suspected to be depressed based on the BDI-II cut-off. The ROC analysis revealed an AUC 
of 0.83, which denotes the BDI-II as an adequate diagnostic measure for this sample, albeit 
less accurate than the previously mentioned studies. Excluding somatic and affective 
depressive symptoms reduced the diagnostic value of the measure with an AUC of 0.82 for 
both ROC analyses.
CFAs were used to assess the fit of the previously described models of the BDI-II items. The 
CFAs revealed adequate fit for all models (see Table 4) based on various fit indices. The 3-
factor model proposed by Buckley and colleagues (2001) was significantly better than the 
two-factor model proposed by Beck and colleagues (1996) and the one-factor model 
indicative of no subscales, as evidenced by its low AIC value. The addition of a higher-order 
factor to the model did not improve fit for the three-factor or two-factor models. These 
findings were consistent across the time1 and 2 samples. All three factors were strongly, 
positively correlated, with the cognitive and affective subscales showing the strongest 
correlation (r = .0.76), followed by somatic and affective (r = 0.75), and cognitive and 
somatic (r = 0.68).
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The current study evaluated the psychometric properties of the BDI-II among a large, 
diverse sample of HIV-positive individuals from the U.S. The BDI-II scores showed good 
internal consistency, test-retest reliability, and predictive validity. Using CFAs, results 
supported the fit of a three-factor model of depression over one-factor and two-factor 
models, and found the addition of a higher-order general depression factor did not improve 
the fit. The sensitivity, specificity, PPV, and NPV of the BDI-II were determined and 
graphed for future use by clinicians and researchers who may choose to use various cut-off 
scores depending on the function of the screening method.
Implications
This is the first study to validate the BDI-II for use among HIV-positive individuals within 
the U.S., which supplements the previous studies conducted with Jamaican and South 
African individuals living with HIV/AIDS. Major depression is prevalent among individuals 
with HIV-infection (Ciesla & Roberts, 2001; Maj et al., 1994; Penzak et al., 2000) and has 
been associated with poor HAART adherence (Ammassari et al., 2004) and higher rates of 
morbidity and mortality (Leserman, 2003).
Although the BDI-II was not designed to be used as a diagnostic tool for major depression 
(Beck et al., 1996), it is commonly employed as a screening assessment in HIV clinics to 
determine which patients will be referred for further evaluation by a mental health 
professional. The diagnostic value of the BDI-II was lower among the current sample than 
other samples of psychiatric and primary care outpatients (Beck et al., 1996). With post-hoc 
ROC analyses, we tested the hypothesis that somatic or affective symptoms, which are 
associated with both depression and HIV illness, would reduce the diagnostic value of the 
BDI-II, however this was not supported and the diagnostic value actually decreased with 
their exclusion.
If the BDI-II is being used to determine the need for mental health triage for HIV-positive 
patients, clinicians may wish to increase their sensitivity at the expense of specificity, to 
ensure that truly depressed patients are not overlooked. Using the cut-off score of 14 derived 
in the original BDI-II validation study provides a sensitivity of 81% and a cut-off score of 
10 provides a sensitivity of 90%. If a clinician is hoping to maximize both sensitivity and 
specificity for the measure, than a cut-off of 17 should be used. Alternatively, researchers 
may wish to increase their specificity if they aim to recruit truly depressed participants. If 
this is the case, a cut-off of 25 provides specificity at 90% and approximately 46% of those 
identified will actually have MDD. It is always recommended that that the presence of MDD 
be confirmed with further assessment and ideally a structured or semi-structured diagnostic 
interview based on DSM-V or ICD-10 criteria.
This was the first study to examine the factor structure of the BDI-II among a large and 
diverse HIV-positive sample collected in the United States. The 3-factor model of the BDI-
II factor structure confirmed as the best model fit in the present study was labeled in 
previous research as cognitive, affective, and somatic depressive symptoms (Buckley et al., 
2001). This finding underlines the multidimensional nature of depressive symptoms and the 
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3-factor solution supported among the current sample is consistent with the solutions found 
in previous studies conducted with HIV-positive participants (Lipps et al., 2010). 
Differences in item factor loadings may result from demographic differences between the 
two samples. In our own review of the factor loadings found in the many studies conducted 
on the BDI and BDI-II, it was rare for two studies to find the same exact factor structure if 
exploratory factor analyses were conducted; however 2-factor and 3-factor solutions 
consistently emerged. Although the addition of a higher-order factor to this model did not 
improve the model fit among the current sample, it also did not decrease the fit of the model 
in a meaningful way. This suggests that a higher-order factor may still be relevant for the 
population.
Limitations
The current data were collected at multiple sites across the United States, suggesting that the 
findings are likely generalizable to many areas in the country. However, data collection 
began nearly a decade ago and certain regions and ethnic groups were not well represented 
in the sample. For example, it is possible that these results do not adequately represent 
Hispanics and Latinos, who account for a slowly increasing number of HIV diagnoses in the 
U.S. (22% in 2011), especially in Massachusetts and Louisiana—two states not represented 
in the current study (CDC, 2011).
Further, the CHARTER study did not include multiple self-report measures of depression 
and therefore did not allow for an examination of convergent and discriminant validity. The 
BDI-II had good convergent and discriminant validity among a sample of Jamaican 
participants with HIV-infection (Lipps et al., 2010) and in other validation studies of various 
psychiatric and general populations (Beck et al., 1996).
It is of note that the time 2 sample in the current study was selected for specified disease 
characteristics of interest to the researchers. Although, these participants were not selected 
based on depression ratings, the time 2 participants had lower BDI-II scores and less MDD 
diagnoses than the time 1 participants. This may have lowered the test-retest reliability 
found in the current study and therefor should be interpreted with caution.
The results of the current study suggest that the BDI-II is an adequate measure for assessing 
depressive symptoms among HIV-positive individuals in the U.S. In light of advances in the 
treatment of HIV and depression, future studies should continue to validate the BDI-II for 
use among HIV-positive populations. Clinics should stay abreast of empirical studies and 
use information regarding sensitivity, specificity, and factor structure to increase their 
accuracy when measuring depressive symptoms among their patients.
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Two-Factor Model derived from Beck et al., 1996 with a higher-order factor.
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Three-Factor Model derived from Buckley et al., 2001 with a higher-order factor.
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Sensitivity and Specificity of the BDI-II. Sensitivity is the proportion of participants 
diagnosed with MDD that are correctly identified by the BDI-II cut-off score. Specificity is 
the proportion of participants not diagnosed with MDD that are correctly identified by the 
BDI-II cut-off score. Correctly diagnosed/ not diagnosed was determined by Composite 
International Diagnostic Interview.
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Positive and negative predictive value of the BDI-II. Positive predictive value (PPV) is the 
probability that a participant has MDD given that they are above the designated BDI-II cut 
off score. Negative predictive value (NPV) is the probability that a participant does not have 
MDD given that they are below the designated BDI-II cut off score. Correctly diagnosed/ 
not diagnosed was determined by Composite International Diagnostic Interview.
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Table 1





n (%) or M (SD) n (%) or M (SD) p
Gender 0.26
 Male 1216 (76.8%) 551 (78.9%)
 Female 367 (23.2%) 147 (12.1%)
Race 0.29
 Black 760 (48.0%) 301 (43.1%)
 White 633 (40%) 303 (43.4%)
 Hispanic 149 (9.4%) 76 (10.9%)
 Other 40 (2.5%) 17 (2,4%)
Age (years) 43.09 (8.5) 43.95 (8.5) 0.03
Years of Education Completed 12.53 (2.6) 12.73 (2.6) 0.08
Disease Status
 AIDS 991 (62.7%) 433 (62.0%) 0.77
 CD4 Absolute 463.15 (287.9) 489.33 (266.8) 0.04
 Viral Load (Log) 2.87 (1.31) 2.64 (1.2) 0.01
Comorbidity Status
 Incidental 867 (54.8%) 421 (60.3%) 0.03
 Contributing 477 (30.1%) 194 (27.8%)
 Confounding 239 (15.1%) 83 (11.9%)
HAND Categories 0.01
 No Impairment 718 (53.4%) 382 (62.1%)
 Asymptomatic 465 (34.6%) 119 (19.3%)
 Mild 122 (9.1%) 94 (15.3%)
 Dementia 39 (2.9%) 20 (3.3%)
Note. AIDS status was determined using CDC criteria (Castro et al., 1992); Details regarding medical comorbidity categories can be found in 
Antinori et al., 2007; HAND= HIV associated neurocognitive disorders; HAND catories were only computed for the participants with incidental 
and contributing medical comorbidity statuses as per guidelines in Antinori et al., 2007.
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Table 2





n (%) n (%) p
Psychiatric
 Current MDD 227 (14.5%) 79 (11.4%) 0.05
 Lifetime MDD 802 (51.2%) 380 (54.9%) 0.10
 Current Dysthymia 13 (0.8%) 2 (0.3%) 0.33
 Lifetime Dysthymia 34 (2.1%) 24 (3.4%) 0.19
Substance Use
 Any Current Substance Use 50 (3.2%) 22 (3.2%) 0.94
 Any Lifetime Substance Use 1152 (72.8%) 509 (72.9%) 0.94
 Current Alcohol 25 (1.6%) 10 (1.4%) 0.91
 Lifetime Alcohol 868 (54.8%) 387 (55.4%) 0.92
 Current Cannabis 17 (1.1%) 4 (0.6%) 0.48
 Lifetime Cannabis 471 (29.8%) 204 (29.2%) 0.91
 Current Cocaine 0 (0.0%) 0 (0.0%) N/A
 Lifetime Cocaine 676 (42.7%) 289 (41.4%) 0.78
 Current Methamphetamine 10 (0.6%) 8 (1.1%) 0.42
 Lifetime Methamphetamine 271 (17.1%) 122 (17.5%) 0.93
 Current Hallucinogen 0 (0.0%) 0 (0.0%) N/A
 Lifetime Hallucinogen 120 (7.6%) 46 (6.6%) 0.66
 Current Inhalant 0 (0.0%) 0 (0.0%) N/A
 Lifetime Inhalant 55 (3.5%) 22 (3.2% 0.87
 Current Opioid 2 (0.1%) 0 (0.0%) 0.61
 Lifetime Opioid 269 (17.0%) 119 (17.0%) 0.94
 Current PCP 0 (0.0%) 0 (0.0%) N/A
 Lifetime PCP 44 (2.8%) 21 (3.0%) 0.90
 Current Sedative 0 (0.0%) 0 (0.0%) N/A
 Lifetime Sedative 123 (7.8%) 50 (7.2%) 0.83
 Current Other 0 (0.0%) 0 (0.0%) N/A
 Lifetime Other 36 (2.3%) 18 (2.6%) 0.86
Note. MDD= major depressive disorder; PCP= phencyclidine
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Table 3
Beck Depression Inventory-II Statistics
Time 1 Sample Time 2 Sample
BDI-II Item n M (SD) Range n M (SD) Range Test-retest r
Sadness 1579 0.45 (0.66) 0-3 698 0.40 (0.62) 0-3 0.60***
Pessimism 1579 0.55 (0.76) 0-3 698 0.48 (0.68) 0-3 0.65***
Past-Failure 1579 0.77 (0.86) 0-3 698 0.59 (0.77) 0-3 0.74***
Loss of Pleasure 1579 0.71 (0.75) 0-3 698 0.63 (0.72) 0-3 0.73***
Guilty Feelings 1579 0.57 (0.67) 0-3 698 0.47 (0.66) 0-3 0.69***
Punishment Feelings 1579 0.49 (0.93) 0-3 698 0.38 (0.82) 0-3 0.59***
Self-Dislike 1579 0.66 (0.89) 0-3 698 0.51 (0.79) 0-3 0.64***
Self-Criticalness 1578 0.64 (0.85) 0-3 698 0.55 (0.81) 0-3 0.58***
Suicidal Thoughts or Wishes 1578 0.23 (0.47) 0-3 698 0.20 (0.41) 0-2 0.70***
Crying 1578 0.55 (0.90) 0-3 698 0.46 (0.83) 0-3 0.53***
Agitation 1579 0.57 (0.79) 0-3 697 0.47 (0.71) 0-3 0.54***
Loss of Interest 1579 0.70 (0.86) 0-3 698 0.61 (0.80) 0-3 0.70***
Indecisiveness 1579 0.58 (0.80) 0-3 698 0.46 (0.72) 0-3 0.71***
worthlessness 1578 0.42 (0.71) 0-3 698 0.38 (0.68) 0-3 0.69***
Loss of Energy 1579 0.92 (0.71) 0-3 698 0.84 (0.71) 0-3 0.70***
Changes in Sleeping Pattern 1572 1.16 (0.95) 0-3 696 1.05 (0.95) 0-3 0.54***
Irritability 1579 0.58 (0.76) 0-3 698 0.50 (0.72) 0-3 0.62***
Changes in Appetite 1571 0.87 (0.88) 0-3 697 0.79 (0.87) 0-3 0.48***
Concentration Difficulty 1579 0.77 (0.76) 0-3 698 0.63 (0.71) 0-3 0.70***
Tiredness or Fatigue 1579 0.89 (0.79) 0-3 698 0.82 (0.77) 0-3 0.71***
Loss of Interest in Sex 1579 0.90 (0.97) 0-3 698 0.84 (0.95) 0-3 0.75***





















Hobkirk et al. Page 18
Table 4
Confirmatory Factor Analysis of the BDI-II Factor Structure in Time 1 and 2 Samples
χ 2 df RMSEA (<.06) CFI (>.95) TLI (>.95) AIC
Time 1 Sample
 1-factor 2211.2*** 189 0.08 0.94 0.94 54081.1
 2-factor 1878.8*** 188 0.08 0.95 0.95 53856.5
 3-factor 1620.5*** 186 0.07 0.96 0.96 53704.8
 Higher order 2-factor 1878.8*** 188 0.08 0.95 0.95 53856.5
 Higher order 3-factor 1827.3*** 187 0.08 0.95 0.95 53846.4
Time 2 Sample
 1-factor 1149.50*** 189 0.09 0.95 0.95 21505.20
 2-factor 984.19*** 188 0.08 0.96 0.96 21398.00
 3-factor 836.83*** 186 0.07 0.97 0.96 21328.60
 Higher order 2-factor 984.19*** 188 0.08 0.96 0.96 21398.00
 Higher order 3-factor 941.36*** 187 0.08 0.96 0.96 21385.80
Note.
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